Natera (Natera) 3-Year Book Growth Rate : 4.30% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Natera 3-Year Book Growth Rate?

Natera's Book Value per Share for the quarter that ended in Dec. 2023 was $6.40.

During the past 12 months, Natera's average Book Value per Share Growth Rate was 0.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was 4.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was 51.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Natera was 136.70% per year. The lowest was -47.90% per year. And the median was 21.00% per year.

Competitive Comparison of Natera's 3-Year Book Growth Rate

For the Diagnostics & Research subindustry, Natera's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Natera's 3-Year Book Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Natera's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Natera's 3-Year Book Growth Rate falls into.

Natera 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Natera (NAS:NTRA) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Natera 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Natera's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Natera (Natera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Natera Inc (NAS:NTRA) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753

Website

https://www.natera.com

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Executives

Michael Burkes Brophy	officer: Chief Financial Officer	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Steven Leonard Chapman	officer: Chief Operating Officer	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Daniel Rabinowitz	officer: CHIEF LEGAL OFFICER	C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN TX 78753
Jonathan Sheena	director, officer: Chief Technology Officer	C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gail Boxer Marcus	director	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Rowan E Chapman	director	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Matthew Rabinowitz	director, officer: Chief Executive Officer	C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Brinkley Ruth Williams	director	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Robert Alan Schueren	officer: Chief Operating Officer	7400 PASEO PADRE PARKWAY, FREMONT CA 94555
Roelof Botha	director	C/O SEQUOIA CAPITAL, 2800 SAND HILL RD, SUITE 101, MENLO PARK CA 94025
Herm Rosenman	officer: Chief Financial Officer	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Todd C Cozzens	director	ONE FEDERAL STREET, 25TH FLOOR, BOSTON MA 02110
Monica Bertagnolli	director	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Roy D. Baynes	director	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130